483
Baxter Oncology GmbHFDA 483 - Baxter Oncology GmbH - September 26, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
The FDA inspected Baxter Oncology GmbH in Halle (Westf.), Germany, and issued a Form 483 with 12 observations. The inspection revealed significant deficiencies in aseptic processing, sterilization validation, environmental monitoring, quality control, and document management, indicating a high risk of product contamination and quality issues.
Open in Dashboard
ID · 0d86bbfe-7f41-475c-961e-6a5a661fc1f6